HIGHLIGHTS
- who: Sha-Sha Wang from the Shandong First Medical University, China have published the article: Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient, in the Journal: (JOURNAL)
SUMMARY
RET intergenic fusion, pralsetinib, lung adenocarcinoma, novel intergenic, tyrosine kinase inhibitors A Corrigendum on: Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient. By Wang S-S, Wang F, Zeng Z, Gao F, Liu H-H, Wang . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.